Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The initial results of the treatment of 8 patients with idiopathic and lupus glomerulonephritis with immunovenin intact are reported. Previously the patients had been treated for a long time with combinations of corticosteroids, immunosuppressors and anticoagulants without effect. All patients had an well expressed nephrotic syndrome, 6 patients had initial chronic renal failure. The immunovenin intact treatment was carried out in three day courses of 85 mg/kg/24 h (a total of 250 mg/kg for one course). All patients received two courses of treatment. The patients were followed up for 3 to 30 months (mean 10.0 +/- 3.29). In 4 patients a full clinical remission was achieved. Two patients, after a satisfactory effect of the treatment, died from non-renal causes. The mechanisms of action of immunovenin intact are discussed.
 ...
PMID:[Treatment of chronic glomerulonephritis with high doses of intravenous immunoglobulin]. 239 19

Fourteen of 52 unselected patients with systemic lupus erythematosus (SLE) (27%) had ligamentous derangement demonstrated by either Jaccoud's syndrome and/or patellar tendon elongation. Three cases had only Jaccoud's syndrome, 4 isolated patellar tendinous laxity, while the remaining 7 presented both findings. Jaccoud's syndrome and/or tendinous laxity were not associated to an increased frequency of arthritis, corticosteroid therapy or a longer disease duration, but significantly associated with increased serum PTH levels secondary to chronic renal failure. Hyperparathyroidism secondary to chronic renal failure should, therefore, be considered a potential factor contributing to the development of Jaccoud's syndrome and/or tendinous laxity in patients with SLE.
 ...
PMID:Tendinous laxity and Jaccoud's syndrome in patients with systemic lupus erythematosus. Possible role of secondary hyperparathyroidism. 274 89

We describe a patient with systemic lupus erythematosus, chronic renal failure and secondary hyperparathyroidism who developed laxity and elongation of the patellar tendon, followed by its rupture one year later. Hydroxyapatite and urate crystals were identified from the chalky material surrounding the patellar tendon observed at surgery. These findings suggest that tendon laxity and elongation could possibly be detected before its rupture and that secondary hyperparathyroidism could be considered as another causative factor of tendon damage in patients with systemic lupus erythematosus.
 ...
PMID:Laxity and rupture of the patellar tendon in systemic lupus erythematosus. Association with secondary hyperparathyroidism. 317 17

A 19 year old girl with Systemic Lupus Erythematosus (SLE), in chronic renal failure and on haemodialysis, underwent tricuspid valve replacement with a Carpentier-Edwards xenograft because of a large calcified mass invading the right side of the heart. The mass caused no symptoms and had been discovered accidentally on a routine chest X-ray. The bioprosthetic valve had subsequently to be removed, having developed functional stenosis, and was not replaced. Despite the absence of a tricuspid valve, the patient remains well five years after the operation.
 ...
PMID:Bioprosthetic valve excision without replacement in the tricuspid position in a patient with Libman-Sacks endocarditis. 337 99

This article examines contraception in adolescents with hematologic, oncologic, dermatologic, and psychiatric disorders, connective tissue diseases, and renal disease and transplants. Teens with iron-deficiency anemia or heavy menstrual flow who need contraception could benefit from oral contraceptives. The IUD is contraindicated for these teens. The IUD is also contraindicated in females with hemorrhagic disease, and hormonal contraceptives are a more appropriate choice for these females. Teens with sickle cell hemoglobinpathies should not use the IUD. Safe use of oral contraceptives (OCs) is questionnable for these teens. The best choice would be barrier methods. Concerns regarding contraception in teens with tumors are mainly 2-fold: effects of pregnancy or contraception on the tumor, and effects of the tumor or tumor therapy on pregnancy and fertility. Therapy including drugs and radiation can have profound effects on the fetus and future fertility. There seems to be no indication that pregnancy has adverse effects on nonhormonal-dependent tumors common in young adults. Malignant melanoma has a strong positive relationship with the use of OCs. OCs have been reported to be helpful in some chronic skin disorders. OCs may not be appropriate for teens who are taking antidepressants or who have a history of depression, although there are contradictory reports in the literature on the effect of the pill on depression. It is helpful for contraceptive services for mentally ill women to be provided by specially trained individuals who are able to obtain informed consent, while taking into account the specific needs of the psychiatrically impaired individual. There are special concerns in prescribing contraception to the mentally retarded teen. Combinations OCs should probably be avoided in adolescents with systemic lupus erythematosus. Because teens with severe chronic renal failure or those on hemodialysis are usually infertile, contraception is less of an issue than for other teens. A barrier method woudl be the msot appropriate method for such teens if they need contraception.
 ...
PMID:Contraceptive use in the chronically ill adolescent female. Part II. 353 Nov 20

A 10 year retrospective analysis of the clinical features and survival of 24 Singapore children with systemic lupus erythematosus was made. The female to male sex ratio was 11:1. The median age at diagnosis was 9.3 years (range: 3.5-17.6 years), and the median duration of follow-up was 3.6 years (range: 3 months-10 years). The common modes of presentation were prolonged fever and malar rash (both 46%). Renal involvement (71%) was frequent. There were six deaths, three from chronic renal failure, two from infection, and one from carditis. The overall survival at 5 years was 0.800 (s.e.m. = 0.090), and at 10 years 0.698 (s.e.m. = 0.103). The survival for lupus nephritis was 0.727 at 5 years (s.e.m. = 0.116), and 0.586 at 10 years (s.e.m. = 0.130). Although the 5 year survival rate is comparable with other series, there were more deaths after the first 5 years, and morbidity from the disease as well as from therapy was considerable.
 ...
PMID:A 10 year review of systemic lupus erythematosus in Singapore children. 366 78

Out of 2,474 bone marrow biopsies we have observed 330 cases (13.3%) with presence of lymphoid nodules (LN). LN were frequent in old age (24.6% over 80 years), in females (17%) and in some diseases, such as rheumatoid arthritis and systemic lupus erythematosus (73.7% of the cases), partial aplasia (34%), hypersplenism (30.4%), hemopoietic dysplasia (25%), chronic renal failure (20.4%), polycythemia vera (20.2%), idiopathic thrombocytopenic purpura (18.8%), acute leukemia (17.7%). Nodular lymphoid hyperplasia of the bone marrow was found especially in systemic autoimmune diseases (26.3%), hypersplenism (9.8%), preleukemia (7.3%) and acute leukemia (4.2%). The presence of excessive medullary LN could indicate a bone marrow microenvironment damage, possibly of autoimmune origin.
 ...
PMID:Lymphoid nodules and nodular lymphoid hyperplasia in bone marrow biopsies. 393 2

The clinical courses of 36 patients with systemic lupus erythematosus (SLE) in whom chronic renal failure developed and who required dialysis for more than three months were studied. At the time dialysis was initiated, 14 of 36 patients (38.9 percent) had clinically active SLE, but only three of 24 (12.5 percent) had activity in subsequent years while receiving dialysis therapy. In the majority of patients, however, renal disease progressed to end-stage despite clinical quiescence of SLE. During the follow-up period (mean +/- SD, 36 +/- 39.8 months), eight patients died--six from infections and two from cardiac disease. Actuarial survival rates at one, two, and five years after dialysis treatment were 91.1, 78.8, and 68.9 percent, respectively. This study suggests that the progression of renal disease to end-stage in patients with SLE may be mediated by nonimmunologic mechanisms as well as SLE-related immunologic insults. In most of these patients undergoing long-term dialysis, SLE remains clinically inactive despite persistent serologic abnormalities. Survival of the patients undergoing dialysis is comparable with that of the general dialysis population.
 ...
PMID:Systemic lupus erythematosus in patients with chronic renal failure. 635 15

Endralazine, a new peripheral vasodilator, was studied in 21 patients with hypertension and chronic renal failure. Nineteen patients had unacceptable control of hypertension with their previous therapy, and 2 were suffering adverse effects for other third line drugs. All patients continued to receive a beta-adrenergic blocking agent. Five patients failed to complete the study, two because of poor compliance, and 3 as a result of failure to control raised blood pressure. In the remaining 16 patients, satisfactory blood pressure reduction was seen at 6 months and was maintained in 12 patients followed for 18 months. Endralazine was well tolerated. No patient developed the lupus syndrome nor evidence of drug-induced immunological abnormality.
 ...
PMID:Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension. 664 4

Two patients with patellar tendon rupture and underlying systemic disease are described. One had systemic lupus erythematosus and the other had chronic renal failure and secondary hyperparathyroidism. There have been 13 other cases of patellar tendon rupture in patients with systemic disease reported in the literature and they are reviewed. Patellar tendon rupture has occurred spontaneously in more than one-half of the cases and has been associated with rupture of the contralateral extensor tendon mechanism in 87%. Although patellar tendon rupture almost always occurs at the tendinous insertion, on a rare occasion (as in one case described in this report), the tear may involve the main substance of the tendon, which is the part of the tendon with the greatest tensile strength. The relation between systemic disease and patellar tendon rupture is discussed and the clinical and radiographic findings are described.
 ...
PMID:Patellar tendon rupture with underlying systemic disease. 677 17


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>